Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 3.

Journal Article

Andreadis, C., Tam, C. S., Borchmann, P., Jaeger, U., McGuirk, J. P., Holte, H., Waller, E. K., Jaglowski, S., Bishop, M. R., Foley, S. R., Westin, J. R., Fleury, I, Ho, P. J., Mielke, S., Teshima, T., Salles, G. A., Schuster, S. J., Bachanova, V, Maziarz, R. T., Besien, K., V, Izutsu, K., Wagner-Johnston, N. D., Kato, K., Corradini, P., Tiwari, R., Awasthi, R., Lawniczek, T., Eldjerou, L. K. and Kersten, M. J. (2020). Correlation of Bridging Therapy (BT) and Lymphodepleting Chemotherapy (LDC) with clinical outcomes in patients (pts) with relapsed/refractory Diffuse Large B-cell Lymphoma (r/r DLBCL) treated with tisagenlecleucel. Oncol. Res. Treat., 43 (SUPPL 4). S. 62 - 64. BASEL: KARGER. ISSN 2296-5262

Bishop, M. R., Dickinson, M., Purtill, D., Barba, P., Santoro, A., Hamad, N., Kato, K., Sureda, A., Greil, R., Thieblemont, C., Morschhauser, F., Janz, M., Flinn, I, Rabitsch, W., Kwong, Y-L, Kersten, M. J., Minnema, M. C., Holte, H., Chan, E. H. L., Martinez-Lopez, J., Mueller, A. M. S., Maziarz, R. T., McGuirk, J. P., Bachy, E., Le Gouill, S., Dreyling, M., Harigae, H., Bond, D., Andreadis, C., McSweeney, P., Kharfan-Dabaja, M., Newsome, S., Degtyarev, E., Awasthi, R., del Corral, C., Andreola, G., Masood, A., Schuster, S. J., Jaeger, U., Borchmann, P. and Westin, J. R. (2022). Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N. Engl. J. Med., 386 (7). S. 629 - 640. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Borchmann, P., Tam, C. S., Jaeger, U., McGuirk, J. P., Holte, H., Waller, E. K., Jaglowski, S. M., Bishop, M. R., Andreadis, C., Foley, S. R., Westin, J. R., Fleury, I., Ho, P. J., Mielke, S., Salles, G., Maziarz, R. T., Anak, Oe, Pacaud, L. B., del Corral, C., Awasthi, R., Agoulnik, S., Tai, F. and Schuster, S. J. (2018). An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Oncol. Res. Treat., 41. S. 36 - 38. BASEL: KARGER. ISSN 2296-5262

This list was generated on Fri Apr 26 16:27:01 2024 CEST.